Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
Read More
Trailing Twelve Months EPS: ($1.03)
2024 EPS Estimate: ($1.65)
2025 EPS Estimate: ($2.05)
- Current Stock Price
- $76.20
- Consensus Rating
- Buy
- Ratings Breakdown
- 15 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $78.00 (2.4% Upside)
